Sandrock Alfred 4

What Happened Alfred Sandrock, President and CEO of Voyager Therapeutics, sold 11,511 shares of Voyager common stock on April 2, 2026. The weighted-average sale price was $3.87 per share, for gross proceeds of about $44,548. The sale was made pursuant to a durable automatic sell instruction to satisfy tax withholding in connection with restricted stock units that vested on April 1, 2026 — not a discretionary trade by the reporting person.

Key Details

• Transaction date: April 2, 2026 (Form filed April 3, 2026) — filing appears timely.
• Price: weighted average $3.87; execution prices ranged from $3.81 to $3.95 across multiple trades.
• Shares sold: 11,511; gross proceeds ≈ $44,548.
• Reason/footnote: sell-to-cover under an automatic instruction adopted May 12, 2025, to satisfy tax withholding for RSU vesting (footnote F1). Reporting person states the sales were not discretionary.
• Footnote F2: price shown is a weighted average; the filer will provide per-trade breakdown on request.
• Shares owned after the transaction: not disclosed in the information provided in this filing.

Context This was a routine sell-to-cover tied to RSU vesting (tax-withholding), a common administrative sale that generally does not signal a voluntary decision to reduce exposure. For retail investors, outright purchases by insiders are typically more informative about insider sentiment; tax-related sales are usually procedural.